Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

The Lower in Vivo Osteogenicity of Adipose Tissue-Derived Stem Cells Correlates with a Higher Innate Immune Response.

Maroquenne M., Bourguignon M., Larochette N., El-Hafci H., Margottin M., Potier E.

Animal Study on Chronic Inflammation, published in Stem Cell Rev Rep (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Rev Rep (2023)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
37642900
DOI
10.1007/s12015-023-10614-1
Citations
2

Abstract (original English)

Abstract Background: Adipose tissue-derived mesenchymal stem cells (ATSCs) have been used as an alternative to bone marrow-derived mesenchymal stem cells (BMSCs) for bone tissue engineering applications. However, the ability of ATSCs to promote new bone formation remains lower than that of BMSCs. The aim of this study was to investigate the mechanisms underlying osteogenicity differences between human ATSCs and BMSCs in tissue-engineered constructs, focusing on the effects of the innate immune response on this process. Methods: In vivo bone formation induced by transplanted human BMSCs and ATSCs combined with ceramic granules was evaluated in an ectopic mouse model. Explants were analyzed by micro-computerized tomographic and histology analyses. Kinetic analyses of both the expressed human and murine genes pertaining to osteogenesis and inflammatory response in tissue constructs explanted at 0, 7, 14, and 28 days post-implantation were performed. The gene expression and secretome profiles of pro-inflammatory cytokines/chemokines in both ATSC and BMSC were analyzed. Results: In contrast to ATSC-containing constructs, which did not induce bone formation, BMSC constructs consistently did so. Implanted BMSCs, concomitantly with host murine progenitors, differentiated into the osteogenic lineage early post-implantation. In contrast, ATSCs differentiated later, when few implanted via

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansMiceAnimalsOsteogenesisCells, CulturedAdipose TissueStem CellsImmunity, Innate

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research